This statistic shows the sales value of the ten most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016. During the measured year, the prescription sales of Harnal, manufactured by Astellas, amounted to around 41.78 million U.S. dollars in South Korea.
Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Pharmaceutical industry in Norway
Overview
5
- Basic Statistic Number of pharmaceuticals available in Norway 2013-2021
- Basic Statistic Leading pharmaceutical companies in Norway 2021, by revenue
- Premium Statistic Leading pharmaceutical companies in Norway 2021, by market share
- Basic Statistic Largest nonprescription pharmaceutical companies in Norway 2021, by market share
- Basic Statistic Public expenditure on blue prescriptions in Norway 2012-2021
Pharmaceutical revenue
5
- Basic Statistic Pharmaceutical revenue in Norway 2012-2021
- Basic Statistic Market share of generic pharmaceuticals in Norway 2013-2021
- Basic Statistic Sales value of nonprescription pharmaceuticals in Norway 2017-2021
- Basic Statistic Sales of pharmaceuticals in Norway by ATC main group 2021
- Basic Statistic Sales volume pharmaceuticals in Norway by drug category 2022
Production and trade
4
- Basic Statistic producer price index of chemical and pharmaceutical products in Norway 2008-2023
- Basic Statistic Number of pharmaceutical preparation enterprises in Norway 2016-2022
- Basic Statistic Number of employees in pharmaceutical industry in Norway 2016-2022
- Basic Statistic Import and export value of basic pharmaceutical products in Norway 2009-2023
R&D, patents and new products
4
- Basic Statistic Number of applications for clinical trials in Norway 2008-2021
- Basic Statistic Number of applications for clinical trials in Norway 2008-2021, by type of actor
- Basic Statistic Number of new and expired active substances in Norway 2013-2021
- Basic Statistic Number of biotechnology patents in Norway 2011-2020
Further related statistics
9
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co total assets 2009-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Alzheimer's amongst older people in 2050: impact of a 5-year delay in onset
- Projected costs of care for older U.S. Alzheimer sufferers 2010-2050
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
Further Content: You might find this interesting as well
Statistics
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co total assets 2009-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Alzheimer's amongst older people in 2050: impact of a 5-year delay in onset
- Projected costs of care for older U.S. Alzheimer sufferers 2010-2050
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
KHIDI. (February 6, 2018). Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars) [Graph]. In Statista. Retrieved June 14, 2024, from https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/
KHIDI. "Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars)." Chart. February 6, 2018. Statista. Accessed June 14, 2024. https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/
KHIDI. (2018). Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars). Statista. Statista Inc.. Accessed: June 14, 2024. https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/
KHIDI. "Sales Value of The 10 Most Prescribed Medications for Benign Prostatic Hyperplasia (Bph) in South Korea in 2016 (in Million U.S. Dollars)." Statista, Statista Inc., 6 Feb 2018, https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/
KHIDI, Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars) Statista, https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/ (last visited June 14, 2024)
Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016 (in million U.S. dollars) [Graph], KHIDI, February 6, 2018. [Online]. Available: https://www.statista.com/statistics/863815/south-korea-prostatic-hyperplasia-most-prescribed-medications-sales-value/